mimmo6
Nuovo Utente
- Registrato
- 12/8/01
- Messaggi
- 3.946
- Punti reazioni
- 157
Allarghiamo gli orizzonti.
Titolo quotato sulla borsa ustraliana. Imugene Limited
(ASX:IMU)
Traduzione Google.
Il vaccino contro il cancro di Imugene produce risultati promettenti nella sperimentazione del cancro gastrico
Di Lorna Nicholas -
Google Traduttore
L'imugene prepara un vaccino antitumorale rivoluzionario contro il mimotopo
Google Traduttore
Imugene fa incursioni nella resistenza al melanoma tramite il candidato alla droga arginina
Google Traduttore
L'imugene prepara un vaccino antitumorale rivoluzionario contro il mimotopo
Google Traduttore
Description
Imugene Limited is an immuno-oncology focused biopharmaceutical company. The Company is engaged in the research and development of human epidermal growth factor receptor 2 positive (HER2 +ve), and gastric and breast cancer vaccines. The Company is also engaged in the research, development and commercialization of health technologies. HER-Vaxx is a cancer immunotherapy designed to treat tumors that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. HER-Vaxx has completed a Phase I clinical trial with over 10 HER-2 positive patients with metastatic breast cancer. It was shown in pre-clinical studies and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu. HER-Vaxx has stimulated the production of HER-2 antibodies in early-stage cancer patients enrolled in the initial clinical trial. The Company is also developing mimotope-based immunotherapies against validated and
oncology targets.
Titolo quotato sulla borsa ustraliana. Imugene Limited
(ASX:IMU)
Traduzione Google.
Il vaccino contro il cancro di Imugene produce risultati promettenti nella sperimentazione del cancro gastrico
Di Lorna Nicholas -
Google Traduttore
L'imugene prepara un vaccino antitumorale rivoluzionario contro il mimotopo
Google Traduttore
Imugene fa incursioni nella resistenza al melanoma tramite il candidato alla droga arginina
Google Traduttore
L'imugene prepara un vaccino antitumorale rivoluzionario contro il mimotopo
Google Traduttore
Description
Imugene Limited is an immuno-oncology focused biopharmaceutical company. The Company is engaged in the research and development of human epidermal growth factor receptor 2 positive (HER2 +ve), and gastric and breast cancer vaccines. The Company is also engaged in the research, development and commercialization of health technologies. HER-Vaxx is a cancer immunotherapy designed to treat tumors that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. HER-Vaxx has completed a Phase I clinical trial with over 10 HER-2 positive patients with metastatic breast cancer. It was shown in pre-clinical studies and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu. HER-Vaxx has stimulated the production of HER-2 antibodies in early-stage cancer patients enrolled in the initial clinical trial. The Company is also developing mimotope-based immunotherapies against validated and
oncology targets.